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and artemether-lumefantrine fixed dose
combinations for the treatment of uncomplicated
Plasmodium falciparum malaria: two open-label,
randomized trials in Nimba County, Liberia
Birgit Schramm1*, Parastou Valeh1, Elisabeth Baudin1, Charles S Mazinda1, Richard Smith1, Loretxu Pinoges1,
Timothy Sundaygar1, Yah M Zolia2, Joel J Jones2, Eric Comte3, Arnaud Bruneel4, Michel Branger5, Vincent Jullien6,
Gwenaelle Carn7, Jean-René Kiechel7, Elizabeth A Ashley1 and Philippe J Guérin1,8Abstract
Background: Safety surveillance of widely used artemisinin-based combination therapy (ACT) is essential, but
tolerability data in the over five years age group are largely anecdotal.
Methods: Two open-label, randomized trials were conducted in Nimba County, Liberia: i) the main tolerability trial
with 1,000 Plasmodium falciparum malaria patients aged over five years (Study-T), and, ii) an efficacy trial with a
secondary objective of collecting tolerability data among 300 children age six to 59 months (Study-E). In both studies
patients were randomized to fixed-dose artesunate-amodiaquine (ASAQ Winthrop®) or artemether-lumefantrine
(AL, Coartem®), respectively. Clinical- and laboratory-adverse events (AEs) were recorded until day 28.
Results: Study-T: most patients experienced at least one AE. Severe AEs were few, primarily asymptomatic blood
system disorders or increased liver enzyme values. No treatment or study discontinuation occurred. Mild or moderate
fatigue (39.8% vs 16.3%, p < 0.001), vomiting (7.1% vs 1.6%, p < 0.001), nausea (3.2% vs 1.0%, p = 0.01), and anaemia
(14.9% vs 9.8%, p = 0.01) were more frequently recorded in the ASAQ versus AL arm. Study-E: mild or moderate AEs
were common, including anaemia, fatigue, vomiting or diarrhoea. The few severe events were asymptomatic blood
system disorders and four clinical events (pneumonia, malaria, vomiting and stomatitis).
Conclusion: Both ASAQ and AL were well tolerated in patients of all age groups. No unexpected AEs occurred. Certain
mild or moderate AEs were more frequent in the ASAQ arm. Standardised safety surveillance should continue for all
forms of ACT.
Trial registration: The protocols were registered with Current Controlled Trials, under the identifier numbers
ISRCTN40020296, ISRCTN51688713, (http://www.controlled-trials.com).
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Artemisinin-based combination therapy (ACT) is a key
tool in malaria control and is the World Health Organiza-
tion’s (WHO) recommended treatment for uncomplicated
Plasmodium falciparum malaria. Among the most widely
available current ACT are artemether-lumefantrine (AL)
and artesunate-amodiaquine (AS +AQ). Artemisinin and
its derivatives are well tolerated [1], and the combination
treatments AS + AQ and AL are considered safe and effi-
cacious [2-4]. Serious safety issues were noted in the past
in association with AQ administered alone at high-dose
for treatment or long-term prophylaxis, with case reports
of severe adverse events (AEs) of agranulocytosis, hepatitis
[5-7], or severe neurotoxicities (involuntary movements/
dystonia) [8]. A dose-dependent risk for neutropaenia was
recently reported for seven-day artesunate monotherapy
(at higher than usual dose: 6 mg/kg/day) in adult malaria
patients [9]. A recent review discussed case reports of
delayed hemolytic anemia following treatment of severe
malaria with artemisinin-derivates, but the data were
considered insufficient to conclude on an association with
artesunate treatment [10]. Hemolytic anemia is also known
to occur as a consequence of malaria infection itself.
Ideally ACT should be provided as fixed-dose combi-
nations (FDC) to improve compliance. The first FDC of
AS with AQ, (ASAQ Winthrop® Sanofi-Aventis) achieved
WHO-prequalification in 2008 and is now registered in 32
countries. Phase III studies showed safety, good tolerability
and high efficacy [4,11,12]. Gathering information on the
safety and tolerability of new products after registration
can be difficult, as pharmacovigilance systems are often
weak or non-existent. The present study aimed to provide
comprehensive information on the clinical and laboratory
tolerability profile of the new ASAQ FDC in a large group
of patients aged six years and older who are studied less
frequently and, unlike younger patients, able to express
symptoms. Complementary safety and tolerability data are
also reported here from a parallel efficacy study on ASAQ
and AL in children under five years [13].
Methods
Study site, objectives and design
Two open-label, randomized, controlled, two-arm clinical
trials were conducted in the Comprehensive Healthcare
Center (CHC) of Saclepea, Nimba County, Northern
Liberia. Médecins sans Frontières (MSF) Switzerland
coordinated the CHC in collaboration with the Ministry of
Health. Since 2004, AS +AQ co-blister has been provided
as first-line treatment in this area.
Tolerability trial in over five year old patients (Study-T)
The principal objective of the main study reported here
was to describe the tolerability of the fixed dose of
ASAQ (Winthrop FDC) in adults and children aged overfive years with uncomplicated P. falciparum malaria
compared to artemether-lumefantrine (AL) (tolerability
trial, Study-T). Tolerability was assessed based on the
frequency and severity of adverse events. Inclusion criteria
were: age older than five years; weight equal or higher
than 18 kg; fever (axillary temperature ≥ 37.5°C), or
history of fever in previous 48 hours; microscopic
confirmation of asexual stages of P. falciparum or mixed
infection; high probability of attending the follow-up visits;
signed informed consent (responsible caregiver). Exclusion
criteria were: pregnancy; or severe malaria; severe anaemia
(<5 g/dl haemoglobin (Hb)); or full course of AS + AQ or
AL treatment or more than two doses of another anti-
malarial in the past four weeks; or known hypersensitivity
to artemisinin derivates, amodiaquine, or artemether-
lumefantrine; or concomitant febrile illness if additional
medication is required other than antipyretics.
Efficacy trial in under five year old patients (Study-E)
The principal objective of the second study was to assess
the genotyping-adjusted cure rates of ASAQ compared
to AL in 300 children six to 59 months old with uncom-
plicated P. falciparum malaria after 42 days of follow
up (efficacy trial, Study-E) [13]. As a secondary object-
ive the safety and tolerability of ASAQ and AL was
assessed up to day 28. Inclusion criteria were: age six to
59 months; fever (axillary temperature ≥ 37.5°C) or fever
or history of fever in the previous 48 hours; blood smear-
confirmed asexual stages of P. falciparum malaria (P. fal-
ciparum mono-infection) and parasite density between
2000–200,000/μl blood; high probability of attending
follow-up; signed informed consent (responsible care-
giver). Exclusion criteria were: general danger signs; se-
vere/complicated malaria [14]; severe anaemia (<5 g/dl
haemoglobin); full course of the treatments under study in
past 10 days; known hypersensitivity to the study drugs;
concomitant febrile illness other than malaria that may
confound outcome; severe malnutrition (weight-for-
height < 70% of median and/or symmetrical edema involv-
ing at least the feet).
Randomization and blinding
Between September 2008 and May 2009, suspected mal-
aria patients were pre-screened by an HRP-2 rapid diag-
nostic test (Paracheck®), followed by screening with a
clinical examination performed by trained physician
assistants, malaria blood smear, Hb from capillary blood
(HemoCue®), and urine-pregnancy test (females ≥12
years). Patients who met the eligibility criteria of the
respective trials were randomized to ASAQ or AL (ratio
1:1). In Study-T, randomization was stratified by weight
(≤36 kg; >36 kg) to balance treatment allocation between
adults and children. Allocation lists were computer-
generated with a block size of six. The study site was
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in sealed opaque envelopes to be opened by study nurses
in consecutive order at randomization. This was not
disclosed to the medical staff performing the clinical
assessments. The laboratory team was aware of treatment
allocation since samples were taken to measure drug
concentrations of the artemisinin partner compounds
on day 0 and day 7, which required distinction between
treatment arms.
Ethics
The procedures followed were in accordance with the
ethical standards of the Helsinki Declaration. All partici-
pants or responsible caretakers (≥18 years) gave written
informed consent. The Liberian Institute for Biomedical
Research (LIBR) ethics committee, the Ministry of
Health and Social Welfare, Monrovia, Liberia, and the
Comité de Protection des Personnes (CPP) Ile de
France XI (Saint Germain en Laye), France, approved
the studies. The studies were registered at Controlled
Trials (http://www.controlled-trials.com/. ISRCTN5168
8713, ISRCTN40020296).
Treatment
Both treatments were three-day oral regimens. ASAQ
Winthrop® was one dose per day without co-administra-
tion of food, and AL (Coartem®, Novartis) was two doses
per day, six to 12 hours between doses, administered
with a high-fat cookie or breast-feeding encouraged.
Dosage was by weight: ASAQ Winthrop® 5 to <9 kg: one
tablet/day of both AS 25 mg/AQ 67.5 mg; 9 to <18 kg:
one tablet/day of both AS 50 mg/AQ 135 mg; 18 to
36 kg: one tablet/day of both AS 100 mg/AQ 270 mg; ≥
36 kg: two tablets/day of both AS 100 mg/AQ 270 mg.
Coartem® tablet strength was 20 mg artemether/120 mg
lumefantrine: 5 to <15 kg: one tablet/dose; 15 to <25 kg:
two tablets/dose; 25 to <35 kg: three tablets/dose; ≥35
kg: four tablets/dose. All doses were administered in the
study site followed by 30 minutes’ observation. If a dose
was vomited/spat-out within 30 minutes, a full dose was
re-administered. If the re-administered dose was vo-
mited/spat-out within 30 minutes, the patient was with-
drawn and rescue treatment given (parenteral quinine or
intramuscular artemether).
Clinical monitoring and laboratory follow up
At each visit (Study-T: days 0, 1, 2, 7, 28; Study-E: days
0, 1, 2, 3, 7, 14, 21, 28, 35, 42) a standardized symptoms
questionnaire and physical examination were conducted.
A β-human chorionic gonadotropin (βHCG) urine-preg-
nancy test was done on day 0 and 28 for females ≥12
years. In Study-T, malaria blood smears were obligatory
on days 0, 2 and 28. In Study-E blood smears were done
on days 0, 2, 3, 7, 14, 21, 28, 35, 42. On day 0 a serumsample (from venous blood) was stored at −20°C for
further analyses. The routine assessment of blood levels
of liver enzymes aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) was implemented after
the start of the tolerability trial (Study-T), following the
recommendation of the data safety monitoring commit-
tee. Liver function tests (LFTs) were conducted by as-
sessment of blood levels of AST and ALT (Reflotron
plus®, Roche Diagnostics) on day 0 (fresh serum) and on
day 28 (finger-prick capillary blood). Missing day 0 AST
values (Patients 1 to 306, analyser implemented after
Study-T start) were measured retrospectively from fro-
zen serum (by Modular D/P, Roche Diagnostics) and
added to summary statistics (ALT not sufficiently stable
in frozen serum). Baseline total bilirubin (direct) and
creatinine were assessed retrospectively from day 0
serum by spectrophotometry (Modular D/P, Roche
Diagnostics). Hb was measured on each visit (finger-
prick capillary blood, HemoCue®). A full blood count
(FBC) was done on days 0, 7 and 28 (Act5diff, Beckman
Coulter®), or if the HemoCue® indicated anaemia.
Anti-malarial blood concentrations
In both studies, day 0 and day 7 blood concentrations of
AQ, desethyl-amodiaquine (DEAQ) (ASAQ arm) and
lumefantrine (LF) (AL arm) were measured from dried
spots of venous blood on filter paper using high per-
formance liquid chromatography with ultraviolet or by
tandem-mass spectrometry detection method, respect-
ively [15,16]. Limits of quantification (LOQ) were <5 ng/
ml for AQ or DEAQ, and <200 ng/ml for LF. Day 7
samples collected before day 6 or after day 8 were ex-
cluded from statistical analysis on blood concentrations.
Summary statistics were provided on the safety popula-
tion. The median day 7 blood concentrations were com-
pared between patients with selected AEs of interest and
patients without the respective AEs. These AEs were:
fatigue (pooled AEs of fatigue, asthenia or weakness),
vomiting, nausea, anaemia, or hepatotoxicity (pooled AEs
of jaundice, hepatitis, hepatomegaly, AST and/or ALT) by
two-sample Wilcoxon rank-sum (Mann–Whitney) test.
Viral hepatitis serology
Baseline serum samples from both studies were retro-
spectively subjected to a screen for viral hepatitis sero-
logical markers: a) hepatitis B virus (HBV): hepatitis B
surface antigen (HBs Ag) (Elisa, DiaSorin, Italy); b) if Ag
HBs-positive a test for the presence of Immunoglobulin-
anti-bodies against the hepatitis B core antigen (HBc
IgM) was performed (1:10 dilution; Elisa, DiaSorin); c)
hepatitis C virus (HCV): a test for the presence of
immunoglobulin G anti-bodies to HCV(anti HCV IgG)
(Elisa, Ingen); and, d) for hepatitis E virus (HEV): the
serum of all patients with elevated baseline AST or ALT
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study participation) were tested for the presence of IgM
antibodies to HEV (anti HEV IgM) (Elisa, Dia.Pro).
Sample size
Study-T: one thousand participants allowed to detect a
minimum of 2.7-3.3% difference between relatively low
AE frequencies (1-2% in one study arm, versus 3.7-5.3% in
the other study arm), and a minimum of 8–8.4% differ-
ences for relatively high AE frequencies (25-30% in one
study arm versus 38.4% in the second arm (80% power
and 0.05 significance level) (Power Analysis and Sample
Size calculation Software for Windows, 2007, NCSS, Utah,
USA). The Study-E sample size was powered to assess the
non-inferiority of ASAQ versus AL treatment efficacy [13].
Recording of adverse events and statistical analysis
Clinical- or laboratory signs and symptoms which oc-
curred or worsened at any time after the first drug in-
take up to day 28 were recorded as adverse events (AEs)
in both studies. AEs were defined according to Inter-
national Conference on Harmonisation (ICH) guidelines
for good clinical practice [17]. For each AE, onset date,
severity grade, relationship to study medication (“definitely
unrelated”, “unlikely related” or “possibly related”), ser-
iousness (“serious” or “not serious”), outcome (“completely
recovered”, “ongoing”, “death”, “unknown”, “recovered
with sequelae”), and date were recorded. The severity of
clinical events was graded using the common toxicity
criteria (CTC) AE grading manual (version 3) [18], and
laboratory events with the laboratory section of the
Division of Microbiology and Infectious Diseases (DMID)
severity grading scheme [19]; ≥12 years: adult toxicity
table (May 2011), <12 years: paediatric toxicity table
(February 2003)), applying the following overall severity
grading: grade 1 (mild) = awareness of sign/symptom, eas-
ily tolerated; grade 2 (moderate) = discomfort enough to
cause interference with usual activity; grade 3 (severe) =
incapacitating with inability to work/perform usual activ-
ity; grade 4 = life threatening/or disabling. All randomized
patients exposed to at least one dose of study drug were
analysed (safety population). Before analysis, AEs were
coded into standardized preferred terms (PT) using the
Medical Dictionary for Regulatory Activities (MedDRA,
version 11). AEs were summarized and presented by the
number and percentage of patients with at least one AE of a
specific PT by treatment arm. If one patient experienced
one specific AE several times, the highest severity grade was
considered for AE summary and for analysis. The compari-
son between ASAQ and AL arms in the main tolerability
trial (Study-T) was performed with focus on a set of pre-
selected AEs or pooled AEs of specific interest. Chi-square-
or Fisher’s Exact test were used for comparisons between
treatment groups, with a 5% significance level (two-tailed).No adjustment for multiple testing was made. Summary sta-
tistics (mean, standard deviation (SD)) at baseline and
follow-up visit(s) were displayed for Hb (as measured by
FBC), AST or ALT, neutrophil- and eosinophil counts. The
highest follow-up severity grades versus baseline grades were
displayed in shift tables for all patients for “AST or ALT in-
creased”, or “neutropaenia”. All analyses were performed
with STATA 10.1 (Stata Corp, Texas, USA).
Results
Inclusion and baseline parameters
In Study-T 1,000 patients were randomized, 498 allocated
to the ASAQ arm and 502 to the AL arm (Figure 1). Two
patients participated twice to the study. Their second
participation was not included in the safety analysis
(ASAQ arm, few mild or moderate blood system AEs were
recorded at second participation). Most patients com-
pleted 28 days follow-up. One child (10 year old female,
ASAQ arm) was withdrawn on day 1 due to underlying
severe hepatitis with grade 3 increased ALT, grade 2 in-
creased AST, grade 2 vomiting, and grade 1 fatigue and
fever on day 0, and not improving on day 1. The patient
was commenced on artesunate monotherapy. Retrospect-
ive day 0 serum testing indicated hepatitis B virus (HBV)
infection with a probable recent or active hepatitis at
baseline (HBV sAg and anti-HBVc IgM positive). In
Study-E, 150 patients were randomized to each study
arm (Figure 2). One child participated twice to the
study. The second participation was not included in the
safety analysis (ASAQ arm, mild blood system disorder
AEs were recorded at second participation). In both
studies, baseline characteristics were similar between
treatment arms (Table 1).
Tolerability in patients aged over five years (Study-T)
Most patients experienced at least one AE (Table 2).
These were mainly of mild or moderate severity, and none
led to treatment discontinuation or withdrawal. Fatigue
was the most frequently reported clinical AE (ASAQ: 200
(39.8%); AL: 81 (16.3%); p < 0.001) (Tables 2, 3 and 4).
Gastrointestinal AEs, abdominal pain, anorexia or
vomiting were also common in both arms. Two pa-
tients vomited after treatment intake and doses were
re-administered and well tolerated (ASAQ arm). Fre-
quent laboratory AEs included mild or moderate eosino-
philia, neutropaenia, or anaemia in both arms (Table 2).
Overall, mean Hb, AST or ALT values, neutrophil and
platelet counts remained normal during follow up (see
Additional file 1). An increase in eosinophil counts be-
tween day 0 and day 28 above normal range occurred in
both arms (Additional file 1). Liver abnormalities were al-
most exclusively asymp-tomatic and mildly increased AST
and/or ALT values (Tables 2, 3 and 4, Additional file 1).
No dystonia or other severe neurotoxicities were reported
Allocated to ASAQ
N=498
Exposed to treatment 
N=498 (100%)
Allocated to AL
N=502
N=502 (100%)
Assessed for eligibility
 N=1254∗
N=2 excluded from analysis
(second participation) 
Analysed (safety population)                   N=496 (99.6%) 
Completed 28 days follow up         N=466 (93.6 %)
Premature discontinuation:    N=30 (6.0%)
Lost to follow up     7 (1.4 %)
Withdrawal of consent    1 (0.2 %)
Unable to attend follow up visit on time  14 (2.8 %)
Recurrence of Parasitaemia    3 (0.6 %)
Incorrect enrolment ±    3 (0.6 %)
Incorrect withdrawal ± ±    1 (0.2 %)
Withdrawn for safety reasons ψ 1 (0.2 %)
Analysed (safety population) N=502 (100%)
Completed 28 days follow up             N=478 (95.2%)
Premature discontinuation: N=24 (4.8%) 
Lost to follow up     5 (1.0 %)
Withdrawal of consent     2 (0.4 %)
Unable to attend follow up visit on time      15 (2.9 %)
Recurrence of Parasitaemia      1 (0.2 %)
Incorrect enrolment ±      1 (0.2 %)
Incorrect withdrawal   - 
Withdrawn for safety reason -
Screening failures N=250 (20%)
205 No microscopic confirmation of asexual Pf or mixed infection 
 26  No willingness to attend follow up 
 26 Informed consent not signed 
 10 Pregnancy 
   8  Severe anemia (<5 g/dl Hemoglobin) 
   5 Age ≤ 5 years  
   5 Concomitant febrile illness and medication required
   3 anti-malarial treatment in previous 4 weeks  
Randomized
N=1000 
Exposed to treatment 
Figure 1 Trial profile (study-T, > 5 years).* Prescreened for positive Paracheck®, age >5 years, no signs of severe illness, willingness to attend
the screening for study participation. ± Patient did not meet the inclusion criteria “asexual P. falciparum malaria parasites by blood smear” (had
no asexual parasites on day 0), therefore withdrawn on day 0. ± ± Accidentally discontinued on day 7 (presence of P. falciparum gametocytes by
blood smear initially misinterpreted as failure). ψ Withdrawn on day 1 due to underlying severe hepatitis (positive for Hepatitis B s-antigen and
anti-HBV core-antibody, indicating probable acute hepatitis at baseline).
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mainly asymptomatic laboratory events. Among these
were three severe neutropaenia AEs (definition for severe:
<400 cells/μl in children three months to 12 years, <750
cells/μl in ≥12 years [19]) (Tables 3 and 5), and two severe
thrombocytopaenia AEs (both patients had elevated
thrombocyte counts at baseline) (Table 3). Four patients
had severe increased ASTAEs, one patient in combination
with a severe increased ALT (Table 3). Two of these pa-
tients (one in each arm) had normal or mildly increased
liver-function-tests (LFTs) at baseline and their LFTs im-
proved to grade 1 or 2 during post-study follow up. They
were both non-reactive for Hepatitis B, C or E virus tests.
The other two patients had already severely increased
AST and/or ALT at baseline and experienced further in-
crease without clinical manifestation during follow up
(ASAQ arm). Both tested Hepatitis B s-antigen (HBV
sAg)-positive. LFT values did not improve at post-study
follow-up visits at 2 or 3 month after day 0. One patient
presented on day 21 with symptomatic severe hepatitis AE
(onset day 14, 8 year-old female, ASAQ arm) with cough,
yellow eyes, dark yellow urination and grade 4 increased
AST and ALT values and HBV sAg positive. The condition
required no hospitalization. Clinical symptoms and ele-
vated LFTs resolved about one month after diagnosis.The one patient with severe anaemia AE (ASAQ arm, Hb
7.9 g/dl) had grade 2 anaemia at baseline (8.0 g/dl), and
completely recovered during follow up. One serious AE
(SAE), spontaneous abortion, was recorded for a 15 year-old
female patient (ASAQ arm) with a positive day 28 β-HCG
urine-pregnancy test (test negative at inclusion) who
reported symptoms of vaginal discharge and lower abdom-
inal pain (with onset nine days earlier). A sexually transmit-
ted infection was suspected and treated with standard
antibiotics and symptoms subsided. A post-study follow up
urine pregnancy test (day 40) was negative, and spontaneous
abortion diagnosed, declared as - serious AE “possibly re-
lated to study drug”. A retrospective blood β-HCG test on
day 0 serum was positive (601.2 international units per litre
(IU/L)), indicating early pregnancy at inclusion. The direct
comparison between treatment arms on a set of pre-
selected AEs of specific interest revealed significantly higher
frequencies of mild or moderate fatigue, vomiting, anaemia
and nausea in the ASAQ arm (Table 4). These were early
events that largely occurred before day 4, with the exception
of anaemia (Figure 3), and largely resolved before day 28 (fa-
tigue AE both arms: 97% completely recovered; vomiting
AE: ASAQ: 100%, AL: 87.5% completely recovered; nausea
AE: both arms 100% completely recovered; anaemia AE:
ASAQ: 79% and AL: 74% completely recovered).
Allocated to ASAQ
N=150 
Exposed to treatment 
N=150 (100%)
Allocated to AL
N=150 
Exposed to treatment
N=150 (100%)
Randomized
N=300 
Assessed for eligibility
 N=701 ∗
N=1 excluded from
analysis, participated twice 
Analysed (safety population) N=149 (99.3%)
Completed 28 days follow up         N=127 (85.2%)
Completed 42 days follow up         N= 92 (61.3%)
Premature discontinuation (<Day 42)    N= 57 (38.3%) 
Lost to follow up 0 
Withdrawal of consent 0 
Unable to attend follow up visit 0
Serious adverse event 2 (1.4%) 
Recurrence of Parasitaemia            54 (36%) 
Incorrect enrolment # 1 (0.7%)
Screening failures N=401(57.2%) 
   356    < 2000 or  > 200 000 asexual Pf parasites /  µl blood    
   117    No asexual Pf malaria (microscopy)
      8 No informed consent  
      3 Signs of severe/complicated malaria 
      3 Presence of general danger signs  
      2 Severe malnutrition (Weight for Height <70%) 
      2 Concomitant febrile illness 
      2     Low probability of respecting follow-up visits
Analysed (safety population) N=150 (100%)
Completed 28 days follow up N=139 (92.7%)
Completed 42 days follow up      N=104 (69.3%)
Premature discontinuation (<Day 42): N= 46 (30.7%) 
Lost to follow up       0 
Withdrawal of consent      2 (1.3%)
Unable to attend follow up visit      1 (0.7%)
Serious adverse event      1 (0.7%)
Recurrence of Parasitaemia         42 (28%) 
Incorrect enrolment              0 
Figure 2 Trial profile of (Study-E, 6–59 months). * prescreened for positive Paracheck®, age 6–59 months, no signs of severe illness, willingness to
attend the screening for study participation; # patient did not meet the inclusion criteria “asexual parasites density <2,000 or >200,000/μl blood” (parasite
load of 415,082 trophozoites/μl blood), withdrawn on day 0.
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Most children experienced at least one AE. Mild or moder-
ate fatigue, cough, vomiting and diarrhoea were most com-
mon clinical AEs in both arms (Table 2). Mean Hb values
improved from mild anaemia on days 0, 7 to normal on
day 28, and mean neutrophil counts, and AST and ALT
values remained within normal range during follow up (see
Additional file 1). The mean eosinophil count increased
two-fold up to day 28 in both arms (within normal range).
Among laboratory AEs, mild or moderate anaemia and
AST/or ALT increased were frequent. The only clinical
hepatotoxicity was mild jaundice in one patient (AL arm,
outcome recovered, not tabulated). Severe AEs were infre-
quent and included anaemia, thrombocytopaenia, and four
clinical AEs: stomatitis (AL), severe malaria (ASAQ, day 28
P. falciparum malaria re-infection confirmed by parasite
genotyping), severe pneumonia (ASAQ), severe vomiting
(AL, repeated vomiting of the study drug leading to study
discontinuation) (Table 3). The three later events were also
declared as serious AEs since hospitalization was required.
All serious AEs resolved without sequelae.
Blood concentrations of amodiaquine, desethyl-
amodiaquine , lumefantine among patients with certain
adverse events (Study-T and Study-E)
AQ and DEAQ blood concentrations (ASAQ arm) and
LF blood concentrations (AL arm) were assessed fromday 0 and day 7 blood spots. In Study-T, AQ intake
shortly before blood sampling (protocol violation) was
indicated for one patient with quantifiable AQ on day 0,
for one patient with high DEAQ blood concentration
(>200 ng/ml) on day 0, and for four patients with quan-
tifiable AQ on day 7. Four patients had day 7 DEAQ
values <100 ng/ml, suggesting insufficient intake or
malabsorption. One hundred patients in the ASAQ arm
had low day 0 DEAQ concentrations (median 3.9 ng/
ml), indicating AQ intake > four weeks before inclusion
(no deviation). In the AL arm, 19 patients had non-
quantifiable LF values on day 7 (<LOQ 200 ng/ml). Their
day 7 values were set to LOQ/2 (100 ng/ml), since the
LOQ was considered low.
Study-T: Median day 7 DEAQ and LF concentrations are
depicted in Table 6. No differences in DEAQ or LF blood
concentrations, respectively, were identified between pa-
tients with or without selected AEs of interest (Table 6).
The exception was significantly higher day 7-DEAQ con-
centrations found among patients who experienced
vomiting as an AE, than those without (p = 0.003).
Study-E: very recent AQ intake was indicated for six chil-
dren who had quantifiable AQ concentrations on day 0
(range: 3.6–34 ng/ml, n = 3 with detectable DEAQ
(>200 ng/ml)) and five children with quantifiable AQ on
day 7 (range: 2.6-4.2 ng/ml) (protocol violation). Three chil-
dren had non-quantifiable DEAQ on day 7 (<2.5 ng/ml),
Table 1 Patient characteristics at inclusion, safety population (both studies)
Study-T (> 5 years) Study-E (6-59 months)
ASAQ AL ASAQ AL
N = 496 N = 502 N = 149 N = 150
Demographics and parasite load
Sex (male), N (%) 246 (49.6) 248 (50) 86 (57.7) 89 (59.3)
Mean age (in years, Study-T; in months, Study-E) (SD) 17.3 (12.1) 16.5 (10.6) 37.2 (13.7) 37 (13.6)
Mean weight in kg (SD) 38.3 (15.5) 38.2 (15.5) 12.8 (2.5) 12.9 (2.6)
Geometric mean P. falciparum trophozoite density (/μl), (range)* 624 558 20,020 19,151
(16–355,623) (16–285,011) (2,016-415,082) (2,000-194,127)
P. falciparum and P. malariae mixed infection, N (%) 7 (1.4) 9 (1.8) - -
Clinical- and laboratory signs, patients N (%) (any severity grade)
Fever / history of fever in past 48 hrs 491 (99.0) 497 (99.0) 149 (100) 150 (100)
Fatigue 75 (15.1) 76 (15.1) 16 (10.7) 12 (8.0)
Vomiting 48 (9.7) 49 (9.8) 29 (19.5) 21 (14.0)
Diarrhoea 8 (1.6) 11 (2.2) 14 (9.4) 13 (8.7)
Splenomegaly 24 (4.8) 20 (4.0) 21 (14.1) 19 (12.7)
Hepatomegaly 6 (1.2) 7 (1.4) 2 (1.3) 4 (2.7)
Anaemia total 82 (16.5) 80 (15.9) 25 (16.8) 20 (13.3)
Anaemia ≥ grade 3 2 (0.4) 2 (0.4) 10 (6.7) 12 (8.0)
Neutropaenia 1 78 (15.7) 81 (16.1) 21 (14.4) 16 (10.8)
Thrombocytopaenia 2 26 (5.2) 12 (2.4) 6 (4.0) 5 (3.3)
AST increased 38 (8.6) 35 (7.7) 9 (6.1) 10 (6.7)
ALT increased 21 (4.6) 22 (6.2) 3 (2.0) 5 (3.3)
Serum creatinine increased 8 (1.9) 15 (3.6) 1 (0.7) 1 (0.7)
Serum bilirubine (total) increased 12 (2.9) 17 (4.0) 11 (8.0) 13 (9.4)
SD = standard deviation, AST = aspartate aminotransferase, ALT = alanine aminotransferase.
1Neutropaenia: (cells/μl): <12 years: ≤1,200, ≥12 years: ≤1,500.
2Thrombocytopaenia: (cells/μl): <12 years: ≤75,000, ≥12 years: ≤99,999.
Anaemia: Hb: (g/dl): <12 years: ≤10.9, ≥12 years: ≤10.5.
AST or ALT increased: <12 years: ≤ 4.9 × ULN, ≥12 years: ≤2.5 × ULN.
Creatinine increased: <2 years: ≤ 0.8 × ULN, 2- <12 years: ≤1.0, ≥12 years: ≤1.5 × ULN; Bilirubin increased: <12 years or ≥12 years: ≤1.5 × ULN.
Study-T, day 0 measures available:
Hb (Beckman FBC): ASAQ: N = 495, AL: N = 501.
Neutrophil counts: ASAQ: N = 487, AL: N = 496.
Thrombocyte counts: ASAQ: N = 495, AL: N = 501.
AST: ASAQ: N = 441, AL: N = 452.
(Day 0 AST values retrospectively assessed from frozen serum samples: N = 100 ASAQ arm, N = 100 AL arm were included in this table).
ALT: ASAQ: N = 341, AL: N = 352.
Creatinine: ASAQ: N = 412, AL: N = 421 (retrospective from frozen serum).
Bilirubine: ASAQ: N = 413, AL: N = 422 (retrospective from frozen serum).
Study-E, day 0 measures available: Hb (Beckman FBC): ASAQ: N = 146, AL: N = 148, Neutrophil count: ASAQ: N = 139, AL: N = 140.
Thrombocyte count: ASAQ: N = 146, AL: N = 148.
AST: ASAQ: N = 148, AL: N = 150; ALT: ASAQ: N = 148, AL: N = 150.
Creatinine: ASAQ: N = 137, AL: N = 138 (retrospective from frozen serum).
Bilirubine: ASAQ: N = 137, AL: N = 138 (retrospective from frozen serum).
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non-quantifiable day 7 LF concentrations (<LOQ, 200 ng/
ml), which were set as LOQ/2. The median day 7 DEAQ
blood concentration was significantly higher in children
with AE fatigue (p = 0.004) than in children without (ASAQ
arm, Table 7). The median day 7 LF concentrations were
significantly higher in children with anaemia AE than
without (AL arm, p = 0.03), and significantly lower inchildren with any hepatotoxicity AE compared to children
without (p = 0.049) Table 7. Results were comparable
when patients with recent AQ intake (day 0, day 7), low
day 7 DEAQ or non-quantifiable day 7 LF values were ex-
cluded from the analyses (both studies), except signifi-
cantly higher day 7 DEAQ values in patients with any
hepatotoxicity AE (Study-E) when patients with devia-
tions were excluded (p = 0.036) (Table 7 footnote).
Table 2 Summary of adverse events recorded up to day 28, safety population (both studies)
Study-T (> 5 years) Study-E (6-59 months)
Patients N (%) ASAQ AL ASAQ AL
N = 496 N = 502 N = 149 N = 150
AE summary
At least one AE (any grade) 457 (92.1) 453 (90.2) 141 (94.6) 132 (88.0)
At least one AE≥ grade 3 17 (3.4) 8 (1.6) 6 (4.0) 4 (2.7)
Serious AE (SAE) 1 (0.2) * 0 (0) 2 (1.3) 1 (0.7)
AE leading to treatment discontinuation 0 0 0 1 (0.7)
Common clinical- or laboratory AEs (≥5% in at least one study arm, any severity grade) #
Fatigue ** 200 (39.8) 81 (16.3) 43 (28.9) 20 (13.3)
Headache 52 (10.5) 42 (8.4) 2 (1.3) 2 (1.3)
AE Vomiting (any) 35 (7.1) 8 (1.6) 16 (10.7) 10 (6.7)
AE Vomiting (after drug intake) 2 (0.4) 0 9 (6.0) 4 (2.7)
Abdominal pain 29 (5.8) 18 (3.6) 3 (2.0) 4 (2.7)
Anorexia 29 (5.8) 7 (1.4) 2 (1.3) 2 (1.3)
Cough - - 28 (18.8) 21 (14.0)
Diarrhoea 20 (4.0) 14 (2.8) 14 (9.4) 14 (9.3)
Eosinophilia ≠ 144 (29.0) 185 (36.9) 6 (4.0) 9 (6.0)
Neutropaenia 94 (19.0) 110 (21.9) 6 (4.0) 8 (5.3)
Leukopaenia 37 (7.5) 29 (5.8) 10 (6.7) 3 (2.0)
Leukocytosis 21 (4.2) 44 (8.8) 10 (6.7) 11 (7.3)
Anaemia 74 (14.9) 49 (9.8) 34 (22.8) 23 (15.3)
AST increased 17 (3.4) 21 (4.2) 8 (5.4) 12 (8.0)
ALT increased 11 (2.2) 17 (3.4) 10 (6.7) 12 (8.0)
AE = adverse event, AST = aspartate aminotransferase, ALT = alanine aminotransferase.
# This section provides a summary of the most common AEs recorded (≥5%, any treatment arm), regardless of the severity or relationship to the study drug.
In cursive letters: ≥5% in at least one arm of any of the two parallel studies, respectively.
* SAE spontaneous abortion (ASAQ arm, Study-T).
** Pooled were reported events of “weakness”, “fatigue” and “asthenia”.
≠ AE recorded if above normal range (0.2-2.0 < 6 years; 0.3-0.8 × 103/μL ≥ 6 - <12 years, 0.04 -0.4 × 103/μL ≥12 years).
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Retrospective viral hepatitis serology on baseline serum
samples from both studies revealed in the > five years
population (Study-T) around 15% HBV prevalence (HBV
sAg positive), among these about 4% with a probable (re-
cent) active hepatitis (IgM anti-HBc positive). A total of
4% of included patients were identified as HCV carriers
(Study-T). Among children six to 59 months (Study-E),
12% were HBV carriers (HBV sAg positive), and among
these about 5% were also IgM anti-HBc positive. A total
of 4% were HCV carriers (Study-E) (Table 8).
Discussion
The tolerability profile of two widely used fixed-dose ACTs,
ASAQ and AL, for the treatment of uncomplicated
P. falciparum malaria, was assessed in a trial of 1,000 pa-
tients over five years old, an age group not frequently
studied in the past and able to express symptoms. The
findings were complemented with safety data collectedin a parallel trial from 300 children under five years. In
both studies, ASAQ and AL were very well tolerated
and highly efficacious (>90% genotyping-adjusted cure
rates, [13]. Clinical- or laboratory adverse events (AEs)
reported in both studies corresponded closely to abnor-
malities seen in malaria infection itself, and were overall
consistent with recent findings. Severe AEs were few and
mostly laboratory abnormalities, which did not manifest
clinically. Four SAEs were reported. The only SAE in
Study-T was a spontaneous abortion in a 15 years-old pa-
tient, for which a potential drug relationship could not
be excluded, though abortion is also known to occur
frequently in malaria [20]. Among children < 5 years
(Study-E), SAEs were one event of pneumonia and one
case of severe malaria (ASAQ arm), and one severe
vomiting after drug intake (AL arm). All three SAEs were
completely resolved.
Neutropaenia and anaemia AE were frequent in both
studies, with few severe events. The overall effects of
Table 3 Summary of severe adverse events recorded up
to day 28, safety population (both studies)
Study-T (>5 years) Study-E (6–59 months)
Patients N (%) ASAQ AL ASAQ AL
N = 496 N = 502 N = 149 N = 150
AEs with severity grade ≥ 3
Hepatitis 1 (0.2) 0 - -
Stomatitis - - 0 1 (0.7)
Vomiting # - - 0 1 (0.7)
Malaria # - - 1 (0.7) 0
Pneumonia # - - 1 (0.7) 0
Splenomegaly 7 (1.4) 1 (0.2) - -
Thrombocytopenia 2 (0.4) 0 4 (2.7) 1 (0.7)
Leukocytosis 2 (0.4) 4 (0.8) - -
Neutropaenia 2 (0.4) 1 (0.2) - -
Anaemia 1 (0.2) 0 3 (2.0) 1 (0.7)
AST increased 3 (0.6) 1 (0.2) - -
ALT increased 1 (0.2) 0 - -
Hepatomegaly 0 1 (0.2) - -
AE adverse event, AST aspartate aminotransferase,
ALT alanine aminotransferase.
# These severe AEs were also reported as serious AEs (Study-E).
Table 4 Patients with at least one AE of specific interest,
safety population, Study-T (>5 years)
Patients N (%)
ASAQ AL
p-valueN = 496 N = 502
AEs “possibly related to study drug” 382 (77.0) 348 (69.3) 0.006
AEs ≥ grade 3 17 (3.4) 8 (1.6) 0.064
Fatigue (pooled) ** 200 (39.8) 81 (16.3) <0.001
Abdominal pain 29 (5.8) 18 (3.6) 0.091
Diarrhoea 20 (4.0) 14 (2.8) 0.279
Vomiting 35 (7.1) 8 (1.6) <0.001
Vomiting after drug intake 2 (0.4) 0 0.247*
Nausea 16 (3.2) 5 (1.0) 0.015*
Hepatotoxicity *** 23 (4.6) 31 (6.3) 0.283
Rash 4 (0.8) 0 0.061*
Itching 0 0 -
Abnormal movements (Dystonia) 0 0 -
Neutropaenia 94 (19.0) 110 (21.9) 0.246
Anaemia 74 (14.9) 49 (9.8) 0.013
Thrombocytopaenia 4 (0.8) 0 0.061*
AE adverse event; * Fisher exact test; ** Frequencies of reported PTs “weakness”,
“fatigue” and “asthenia” were pooled; *** defined as any or combination of the
following AEs: hepatitis, hepatomegaly, AST and/or ALT increased, jaundice.
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counts in both age-groups were minimal, in line with
recent data [3,21,22]. Eosinophilia was observed in both
studies, likely to reflect helminth infections [23]. Severe
hepatotoxicity, neutropaenia, dystonia, events previously
reported with high-dose AQ [5-8], were of no specific
concern in the present studies, in line with recent trials
on AS + AQ and/or AL tolerability [3,4,11,24-26]. Retro-
spective serology on day 0 serum samples indicated a
high prevalence of chronic Hepatitis B infection among
participants of the tolerability trial (15%). Three of the
HBV-positive patients experienced grade 3 or 4 increased
AST and/or ALT AEs (ASAQ arm). Two had already
entered the trial with asymptomatic but severely elevated
LTF(s) and developed no clinical manifestation during
study follow-up. One HBV-positive patient experienced a
transient symptomatic hepatitis during the study. No spe-
cific medical intervention was indicated and clinical- and
laboratory signs resolved during post-study follow up. In
the second study among children under five years, the
prevalence of indicated chronic HBV infection was also
high (12%). No severe hepatotoxicity AEs were recorded
in this second trial. Taken together, our findings may
suggest that ASAQ and AL are safe and also overall well
tolerated among patients with chronic viral hepatitis, a
condition that is very common in tropic settings where
malaria is endemic. It should be noted however that the
trials were not powered to detect rare events. Further sur-
veillance in this specific sub-population may be required,
including repeated treatments in highly endemic settings.
Recent studies also indicated a potential increase of ad-
verse events among patients co-infected and treated for
both malaria and HIV [27,28]. Information on the HIV-
serostatus of patients in the present studies was not
recorded, but the estimated HIV prevalence in Liberia is
relatively low (1%) [29]. None of the participants reported
antiretroviral treatments among recorded concomitant
medications.
A comparative analysis on the frequency of patients
presenting with adverse events of specific interest was
performed in the main tolerability trial (Study-T). The
only difference identified between treatment arms were
higher frequencies of mild or moderate AEs fatigue,
vomiting, nausea, and anaemia recorded in the ASAQ
arm. The clinical events were mostly early onset
(≤day 3), did not affect treatment intake, and were
largely resolved before day 28.
Mild or moderate fatigue AEs were very frequently
reported in both treatment arms, with almost twice as
many patients in the ASAQ arm than in the AL arm
(39.8% versus 16.3%, p < 0.001). Asthenia is considered
among common undesirable effects of ASAQ Winthrop
(SmPC ASAQ Winthrop®), similar to what is noted for
AL [3]. No differences in fatigue or asthenia between
Table 5 Neutropaenia day 0 severity grade compared to
maximum severity grade at follow up, safety population
Study-T ASAQ AL
(>5 years) N = 482* N = 490*
Neutropenia
grade at day 0
Maximum Neutropenia
grade after day 0
Patients N (%)
0 0 332 (68.9) 325 (66.3)
1 0 33 (6.8) 25 (5.1)
2 0 2 (0.4) 2 (0.4)
missing 0 3 (0.6) 3 (0.6)
0 1 59 (12.2) 73 (14.9)
1 1 28 (5.8) 31 (6.3)
2 1 3 (0.6) 7 (1.4)
3 1 0 (0.0) 2 (0.4)
missing 1 4 (0.8) 3 (0.6)
0 2 6 (1.2) 7 (1.4)
1 2 6 (1.2) 5 (1.0)
2 2 6 (1.2) 2 (0.4)
3 2 0 (0.0) 1 (0.2)
1 3 2 (0.4) 1 (0.2)
3 3 1 (0.2) 0 (0.0)
Any worsening after baseline 73 (15.1) 86 (17.6)
Study-E ASAQ AL
(6-59 months) N = 142* N = 143*
Neutropenia
grade at day 0
Maximum Neutropenia
grade after day 0
Patients N (%)
0 0 121 (85.2) 125 (87.4)
1 0 3 (2.1) 3 (2.1)
missing 0 9 (6.3) 7 (4.9)
0 1 6 (4.2) 6 (4.2)
1 1 3 (2.1) 2 (1.4)
Any worsening after baseline 6 (4.2) 6 (4.2)
* Shift tables were created for all patients with at least one neutrophil count
available after day 0.
0
10
20
30
40
ASAQ AL ASAQ AL ASAQ AL ASAQ AL
%
 
Pa
tie
nt
s 
w
ith
 a
t l
e
a
st
 
o
n
e 
AE
Fatigue VomitingNausea
AE onset  between Days 0-3
AE onset  between Days 4-28
Anemia
Figure 3 Onset period of specific AEs of interest
(Study-T, >5 years). AE = adverse event. Depicted are the percentage
of patients who had at least on AE fatigue, vomiting, nausea or anaemia,
respectively, classified by event onset time period; i e, between day 0
after treatment intake and day 3, or between day 4 and day 28,
respectively, by treatment arm. Safety population.
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studies [11,24,30,31]. In the present trials, fatigue was
among the symptoms prompted by the physicians during
clinical examination, and some degree of over-reporting
of more subjective symptoms such as fatigue cannot be
fully excluded in an open-label trial.
Among gastrointestinal AEs, mild or moderate vomiting
AE was about four times more frequently reported in the
ASAQ arm. The incidence of early vomiting immediately
after drug intake though was reassuringly low in both
study arms. Recent trials conducted in Ghana, Senegal
and Ivory Coast, respectively, also reported nausea and
vomiting AEs at higher frequency in the AS + AQ arm
when compared to AL [24,30]. No differences in
gastro-intestinal AEs were reported in three other trials[11,24,31]. The impact of such mild or moderate clin-
ical symptoms on real life treatment adherence and
effectiveness would be worthy of further study, taking
into account also other factors such as concomitant
food intake, tablet burden and dosing schedule. In the
present studies, ASAQ was not administered with food,
since a high fat meal may modify the bioavailability of
AS and AQ [32]. Mild or moderate anemia AEs were
also more frequent in the ASAQ arm, similar to one
recent study [30]. Mean Hb values remained within the
normal range in both treatment arms, indicating that a
potential effect of the treatment(s) on haemoglobin
value was overall very moderate. A recent review which
summarized the findings of nine trials in African Coun-
tries on AL versus AS +AQ however did not identify
differences in anemia AEs [21].
The bioavailability of the non-artemisinin partner com-
pound of ACTs may also affect tolerability. Among pa-
tients over five years (Study-T), the day 7 DEAQ-blood
concentration was significantly higher for patients with
vomiting AE compared to patients without vomiting AE.
Among children under five years (Study-E), the findings
were different. Higher day 7-DEAQ values were identified
among children with fatigue or hepatotoxicity AE than
without, and a higher day 7-LF concentration was found
among children with anaemia AE than without. The rele-
vance of these associations is uncertain. Further studies
and pooled data analyses are needed to better interpret
the relationships of blood concentrations, dosage, and
tolerability.
Safety and tolerability monitoring of ASAQ FDC and all
other ACTs should continue in a standardised manner.
Pharmacovigilance networks are not implemented in most
Table 6 Day 7 DEAQ and LF blood concentrations by presence or absence of selected AEs, safety population, Study-T
Study-T ASAQ AL
(>5 years) N = 496 N = 502
AEs of
interest
Patients DEAQ blood concentration p-value Patients LF blood concentration p-value
n/N* [ng/ml] median (IQR) ** n/N* [ng/ml] median (IQR) **
All patients 421/496 466 (352,606) 447/502 505 (I 380,670)
Fatigue (pool)
No AE 250/296 466 (352,605) p = 0.925 376/421 504 (381,659) p = 0.549
AE 171/200 466 (352,606) 71/81 519 (374,709)
Vomiting
No AE 393/461 461 (345,603) p = 0.003 440/494 505 (381,670) p = 0.711
AE 28/35 559 (467, 705) 7/8 463 (277, 828)
Nausea
No AE 407/480 466 (352, 605) p = 0.754 443/497 505 (381, 670) p = 0.111
AE 14/16 457 (387, 648) 4/5 245 (100, 549)
Anaemia
No AE 350/422 462 (352, 604) p = 0.162 403/453 505 (381, 701) p = 0.745
AE 71/74 517 (345, 677) 44/49 508 (374, 616)
Hepatotoxicity
No AE 402/473 465 (352, 606) p = 0.512 418/471 506 (378, 681) p = 0.882
AE 19/23 485 (407, 586) 29/31 477 (416, 659)
* n/N = number of blood samples available and quantifiable (n) among total patients with or without AE (N); ** Two-sample Wilcoxon rank-sum (Mann–Whitney) test.
Table 7 Day 7 DEAQ and LF blood concentrations by presence or absence of selected AEs, safety population, Study-E
Study-E ASAQ AL
(6–59 months) N = 149 N = 150
AEs of
interest
Patients DEAQ blood concentration p-value Patients LF blood concentration p-value
n/N* [ng/ml] median (IQR) ** n/N* [ng/ml] median (IQR) **
All patients 137/149 423 (314,602) 139/150 310 (200,447)
Fatigue (pool)
No AE 93/105 396 (302,529) p = 0.004 122/130 332 (200,447) p = 0.332
AE 44/44 501 (354,794) 17/20 256 (100,344)
Vomiting
No AE 122/133 435 (314,602) p = 0.725 130/140 313 (200,447) p = 0.428
AE 15/16 366 (277,743) 9/10 256 (100,329)
Nausea
No AE 137/149 423 (314,602) na 138/149 310 (200,447) na
AE 0/0 - 1/1 256
Anaemia
No AE 105/115 423 (310,554) p = 0.455 116/127 305 (150,431) p = 0.030
AE 32/34 443 (332,739) 23/23 380 (262,566)
Hepatotoxicity
No AE 125/136 416 (311,554) p = 0.065# 121/132 329 (217,457) p = 0.049
AE 12/13 569 (354,934) 18/18 150 (100,409)
AE= adverse event; * n/N = number of blood samples available and quantifiable (n) among total patients with or without AE (N); ** Two-sample Wilcoxon rank-sum
(Mann–Whitney) test; # When patients with deviations (quantifiable AQ on day 0 or day 7) were excluded from this comparative analysis (n = 6): p = 0.036.
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Table 8 Baseline viral hepatitis serology, safety
population
Patients n/N (%)
ASAQ AL
Study-T (>5 years) N = 496 N = 502 Total
HBV sAg positive 73/457 (15.9) 70/467 (14.9) 143/924 (15.5)
HBV anti-HBVc positive # 4/73 (5.5) 2/70 (2.8) 6/143 (4.2)
HCV antibody positive 18/455 (4.0) 19/466(4.1) 37/921 (4.0)
HEV anti-IgM positive* 0/33 (0) 0/34(0) 0/67 (0)
ASAQ AL
Study-E (6-59 months) N = 149 N = 150 Total
HBV sAg positive 18/148 (12.1) 18/150 (12.0) 36/298 (12.1)
HBV anti-HBVc positive # 1/18 (5.5) 1/18 (5.5) 2/36 (5.5)
HCV antibody positive 7/147 (4.8) 4/148 (2.7) 11/295 (3.7)
HEV anti-IgM positive* 0/5 (0) 0/7 (0) 0/12 (0)
HBV Hepatitis B Virus, HCV Hepatitis C Virus, HEV Hepatitis E Virus, Ag antigen.
Displayed are percentages of patients who tested positive among those with
available test results.
# anti-HBVc was assessed for HBV sAg positive patients.
* HEV anti-IgM was assessed for patients with elevated AST or ALT (values 2×
upper limit normal range) at any point during study participation, and/or any
AE “hepatotoxicity” among Study-T participants.
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formation on safety and tolerability thus relies on individ-
ual studies. The need of standardized guidelines for
adverse event monitoring of ACTs was recently empha-
sized [33,34]. More information on the tolerability of ACT
specifically for patients suffering from chronic (viral) hepa-
titis, and/or HIV infection would also be of use.
Conclusions
These findings confirmed the good tolerability of ASAQ
FDC (Winthrop®) and AL (Coartem®) in patients of all
ages in Liberia. Hepatotoxicity, neutropenia or dystonia
were of no specific concern in the present studies. Toler-
ability monitoring of ASAQ FDC should continue, as for
all widely used ACT.
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